Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 15

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 15
---
 previous availability at 10 weeks.

◦Earlier prenatal screening with Prequel enables earlier risk assessment for fetal chromosomal abnormalities, allowing expectant parents and healthcare providers to make more informed decisions sooner.

•Expanded Carrier Screening with Foresight

◦Increased the number of conditions screened by Foresight Universal Plus, our expanded carrier screen, to 272 genes.

◦Aligned with ACMG recommendations and anticipated guidance from the American College of Obstetricians and Gynecologists, ensuring clinical relevance and broad adoption.

•Advancements in MRD Testing

◦Completed and presented analytical assessments at multiple conferences demonstrating the exceptional sensitivity of Precise MRD, our research-use-only MRD product.

◦We have partnered in several clinical validation studies in breast cancer and renal cancer with leading institutions, including:

▪MD Anderson Cancer Center

▪Memorial Sloan Kettering Cancer Center

▪University of Rochester Medical Center

•Global Collaboration on MRD Research

◦Began processing samples for MONSTAR-3, a prospective pan-cancer MRD study, led by collaborators at the National Cancer Center East in Japan.

◦Supported the continued development of MRD as a potential tool for monitoring cancer recurrence and treatment response.

These strategic R&D investments and collaborations underscore our commitment to innovation, regulatory alignment, and improved clinical utility for our current and future testing products. We believe that by advancing the capabilities of our screening and diagnostic technologies, we continue to drive value for our patients, healthcare providers, and stakeholders. For the years ended December 31, 2024, 2023, and 2022, we incurred research and development expense of $113.4 million, $88.7 million, and $85.4 million, respectively.

8

Table of Contents

Industry and Competition

Healthcare is evolving to be more patient-centered and value-based. Patients, healthcare providers, payors, and health systems are looking to apply the power of genetic insights, molecular diagnostics, and precision medicine to advance care, improve access, and lower costs. We believe key industry trends include the following:

•accelerating shifts in consumer engagement, early detection, home-based care models, the rise of low-cost sequencing, telemedicine, and virtual care; 

•demand for high-quality, clinically validated diagnostics that support early detection and targeted treatment strategies;

•expanding access to genetic insights, particularly among underserved populations with increased focus on health equity, reducing disparities in health care outcomes, and ensuring increased access for challenged communities;

•broader